Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.115 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Transition metal complexes are of increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru(II) polypyridyl complexes have emerged as promising systems for both PDT and PCT. Their rich photochemical and photophysical properties derive from a variety of excited-state electronic configurations accessible with visible and near-infrared light, and these properties can be exploited for both energy- and electron-transfer processes that can yield highly potent oxygen-dependent and/or oxygen-independent photobiological activity. Selected examples highlight the use of rational design in coordination chemistry to control the lowest-energy triplet excited-state configurations for eliciting a particular type of photoreactivity for PDT and/or PCT effects. These principles are also discussed in the context of the development of TLD1433, the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial. The design of TLD1433 arose from a tumor-centered approach, as part of a complete PDT package that includes the light component and the protocol for treating non-muscle invasive bladder cancer. Briefly, this review summarizes the challenges to bringing PDT into mainstream cancer therapy. It considers the chemical and photophysical solutions that transition metal complexes offer, and it puts into context the multidisciplinary effort needed to bring a new drug to clinical trial.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Chemical Reviews
- Topic
- Nanoplatforms for cancer theranostics
- Field
- Engineering
- Canadian institutions
- University Health NetworkPrincess Margaret Cancer CentreIzaak Walton Killam Health CentreDalhousie UniversityAcadia University
- Funders
- Basic Energy SciencesNational Cancer InstituteCanadian Institutes of Health ResearchCanada Foundation for InnovationBeatrice Hunter Cancer Research InstituteNova Scotia Research Innovation TrustNatural Sciences and Engineering Research Council of CanadaDalhousie Medical Research FoundationAcadia UniversityWelch Foundation
- Keywords
- Photodynamic therapyChemistryContext (archaeology)PhotosensitizerRational designCancer therapyNanotechnologyEnergy transferExcited statePhotochemistryCombinatorial chemistryCancerChemical physicsOrganic chemistryMaterials sciencePhysics
- Has abstract in OpenAlex
- yes